PMID- 28692539
DCOM- 20180514
LR  - 20180523
IS  - 1473-5571 (Electronic)
IS  - 0269-9370 (Linking)
VI  - 31
IP  - 15
DP  - 2017 Sep 24
TI  - HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment.
PG  - 2035-2052
LID - 10.1097/QAD.0000000000001574 [doi]
AB  - : HIV infection has a significant impact on the natural history of chronic
      hepatitis B virus (HBV) infection, with increased levels of HBV DNA, accelerated 
      progression of liver disease and increased liver-associated mortality compared
      with HBV monoinfection. Widespread uptake and early initiation of HBV-active
      antiretroviral therapy has substantially improved the natural history of HIV-HBV 
      coinfection but the prevalence of liver disease remains elevated in this
      population. In this paper, we review recent studies examining the natural history
      and pathogenesis of liver disease and seroconversion in HIV-HBV coinfection in
      the era of HBV-active antiretroviral therapy and the effects of HIV directly on
      liver disease. We also review novel therapeutics for the management of HBV with a
      particular emphasis on clinical strategies being developed for an HBV cure and an
      HIV cure and their impact on HIV-HBV coinfected individuals.
FAU - Singh, Kasha P
AU  - Singh KP
AD  - aThe Peter Doherty Institute for Infection and Immunity, University of Melbourne 
      and Royal Melbourne Hospital bVictorian Infectious Diseases Service, Royal
      Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity
      cDepartment of Infectious Diseases, Alfred Hospital and Monash University,
      Melbourne Australia dThai Red Cross AIDS Research Center and Faculty of Medicine,
      Chulalongkorn University, Bangkok, Thailand.
FAU - Crane, Megan
AU  - Crane M
FAU - Audsley, Jennifer
AU  - Audsley J
FAU - Avihingsanon, Anchalee
AU  - Avihingsanon A
FAU - Sasadeusz, Joe
AU  - Sasadeusz J
FAU - Lewin, Sharon R
AU  - Lewin SR
LA  - eng
GR  - U19 AI096109/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Review
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
PL  - England
JT  - AIDS (London, England)
JID - 8710219
RN  - 0 (Antiviral Agents)
SB  - IM
SB  - X
MH  - Antiviral Agents/*therapeutic use
MH  - Coinfection/drug therapy/*epidemiology/pathology
MH  - *Disease Management
MH  - HIV Infections/*complications/drug therapy/*epidemiology/pathology
MH  - Hepatitis B, Chronic/*complications/drug therapy/*epidemiology/pathology
MH  - Humans
PMC - PMC5661989
MID - NIHMS892024
EDAT- 2017/07/12 06:00
MHDA- 2018/05/15 06:00
CRDT- 2017/07/11 06:00
PMCR- 2018/09/24 00:00
PHST- 2018/09/24 00:00 [pmc-release]
PHST- 2017/07/12 06:00 [pubmed]
PHST- 2018/05/15 06:00 [medline]
PHST- 2017/07/11 06:00 [entrez]
AID - 10.1097/QAD.0000000000001574 [doi]
PST - ppublish
SO  - AIDS. 2017 Sep 24;31(15):2035-2052. doi: 10.1097/QAD.0000000000001574.